Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia
Open Access
- 1 April 1997
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 15 (S2) , 177-181
- https://doi.org/10.1002/stem.5530150823
Abstract
Herein we report on the feasibility of mobilizing peripheral blood progenitor cells (PBPC) in a prospective study of the HOVON‐SAKK Groups in 96 cases with newly diagnosed acute myeloid leukemia (AML). Among 96 patients, 76 patients (79%) entered complete remission. Mobilization was undertaken with variable dosages of G‐CSF in 63 patients, and 54 patients (87%) were leukapheresed. The comparative yields of pheresis following the G‐CSF schedules and hematopoietic recovery data are presented and discussed. PBPC transplantation results in faster hematopoietic regeneration compared to autologous marrow grafting in the prior AML HOVON study. Stem Cells 1997; 15(suppl 1): 177–181Keywords
This publication has 5 references indexed in Scilit:
- A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]Blood, 1996
- Post-Remission Treatment of Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-upBlood, 1988